We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is it a Good Idea to Invest in Immunocore Stock Right Now?
Read MoreHide Full Article
Key Takeaways
Immunocore's Kimmtrak is approved in 39 countries and has been launched in more than 30.
Kimmtrak sales climbed to $106.7M in Q1 2026, reflecting continued commercial momentum.
Immunocore sees growth potential from broader adoption and new treatment settings.
Immunocore (IMCR - Free Report) is witnessing a strong sales uptake for its sole marketed drug, Kimmtrak (tebentafusp-tebn), which is approved for treating patients with unresectable or metastatic uveal melanoma (mUM).
Kimmtrak is approved in 39 countries, including the United States, the European Union and several other countries. The product has been launched in more than 30 countries worldwide and continues to be the standard of care for mUM in most markets where it has been launched.
Kimmtrak generated $400 million in sales in 2025, up almost 29% year over year. Sales of the drug were driven by increased volumes in the United States and Europe as well as expansion into other countries worldwide.
In the first quarter of 2026, sales of Kimmtrak rose 14% year over year to $106.7 million. The strong commercial performance of Kimmtrak is expected to continue through the rest of 2026.
IMCR’s Price Performance
Year to date, shares of Immunocore have plunged 18.8% compared with the industry’s decline of 0.6%.
Image Source: Zacks Investment Research
IMCR Eyes Kimmtrak Label Expansion
Several label expansion studies evaluating Kimmtrak both as monotherapy and in combination with other therapies are currently ongoing, targeting an earlier-line setting for melanoma indications.
Management believes Kimmtrak's growth can be driven by broader adoption in the existing mUM market, potential expansion into second-line and later-stage advanced cutaneous melanoma, and potentially moving into the adjuvant treatment setting for uveal melanoma.
Positive data readouts from ongoing studies and the successful expansion of Kimmtrak into additional indications could serve as an important catalyst for IMCR stock.
IMCR’s Other Pipeline Updates
Immunocore is developing its pipeline candidate, brenetafusp, in combination with Bristol Myers’ (BMY - Free Report) blockbuster cancer drug, Opdivo (nivolumab), in a registrational phase III study for treating first-line advanced cutaneous melanoma.
The candidate is also being investigated in early-to-mid-stage studies both as monotherapy and as combination therapy in multiple tumor types, including ovarian cancer and non-small cell lung cancer.
BMY’s Opdivo is approved across multiple cancer types, including lung, melanoma and kidney cancers. Bristol Myers recorded $2.15 billion in Opdivo sales in the first quarter of 2026.
Immunocore also has a deep pipeline in multiple therapeutic areas. These include clinical and pre-clinical programs in oncology, infectious diseases and autoimmune diseases.
With a strong cash position and some clinical milestones expected later this year, we expect investor focus to remain on IMCR, despite its recent share price decline.
IMCR’s Rank & Rising Estimates
Immunocore has a Zacks Rank #1 (Strong Buy). Over the past 60 days, estimates for Immunocore’s 2026 bottom line have improved from a loss of 88 cents per share to earnings of 6 cents. Over the same period, EPS estimates for 2027 have risen from 24 cents to 87 cents.
Immunocore Holdings PLC Sponsored ADR Price and Consensus
Over the past 60 days, estimates for Liquidia’s 2026 EPS have increased to $2.97 from $1.50. Over the same period, EPS estimates for 2027 have risen to $4.81 from $2.91. LQDA shares have surged 97.2% year to date.
Liquidia’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 54.40%.
View the Zacks #1 Rank List
Image: Bigstock
Is it a Good Idea to Invest in Immunocore Stock Right Now?
Key Takeaways
Immunocore (IMCR - Free Report) is witnessing a strong sales uptake for its sole marketed drug, Kimmtrak (tebentafusp-tebn), which is approved for treating patients with unresectable or metastatic uveal melanoma (mUM).
Kimmtrak is approved in 39 countries, including the United States, the European Union and several other countries. The product has been launched in more than 30 countries worldwide and continues to be the standard of care for mUM in most markets where it has been launched.
Kimmtrak generated $400 million in sales in 2025, up almost 29% year over year. Sales of the drug were driven by increased volumes in the United States and Europe as well as expansion into other countries worldwide.
In the first quarter of 2026, sales of Kimmtrak rose 14% year over year to $106.7 million. The strong commercial performance of Kimmtrak is expected to continue through the rest of 2026.
IMCR’s Price Performance
Year to date, shares of Immunocore have plunged 18.8% compared with the industry’s decline of 0.6%.
Image Source: Zacks Investment Research
IMCR Eyes Kimmtrak Label Expansion
Several label expansion studies evaluating Kimmtrak both as monotherapy and in combination with other therapies are currently ongoing, targeting an earlier-line setting for melanoma indications.
Management believes Kimmtrak's growth can be driven by broader adoption in the existing mUM market, potential expansion into second-line and later-stage advanced cutaneous melanoma, and potentially moving into the adjuvant treatment setting for uveal melanoma.
Positive data readouts from ongoing studies and the successful expansion of Kimmtrak into additional indications could serve as an important catalyst for IMCR stock.
IMCR’s Other Pipeline Updates
Immunocore is developing its pipeline candidate, brenetafusp, in combination with Bristol Myers’ (BMY - Free Report) blockbuster cancer drug, Opdivo (nivolumab), in a registrational phase III study for treating first-line advanced cutaneous melanoma.
The candidate is also being investigated in early-to-mid-stage studies both as monotherapy and as combination therapy in multiple tumor types, including ovarian cancer and non-small cell lung cancer.
BMY’s Opdivo is approved across multiple cancer types, including lung, melanoma and kidney cancers. Bristol Myers recorded $2.15 billion in Opdivo sales in the first quarter of 2026.
Immunocore also has a deep pipeline in multiple therapeutic areas. These include clinical and pre-clinical programs in oncology, infectious diseases and autoimmune diseases.
With a strong cash position and some clinical milestones expected later this year, we expect investor focus to remain on IMCR, despite its recent share price decline.
IMCR’s Rank & Rising Estimates
Immunocore has a Zacks Rank #1 (Strong Buy). Over the past 60 days, estimates for Immunocore’s 2026 bottom line have improved from a loss of 88 cents per share to earnings of 6 cents. Over the same period, EPS estimates for 2027 have risen from 24 cents to 87 cents.
Immunocore Holdings PLC Sponsored ADR Price and Consensus
Immunocore Holdings PLC Sponsored ADR price-consensus-chart | Immunocore Holdings PLC Sponsored ADR Quote
Another Stock to Consider
Another top-ranked stock in the biotech sector is Liquidia Corporation (LQDA - Free Report) , currently sporting a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Liquidia’s 2026 EPS have increased to $2.97 from $1.50. Over the same period, EPS estimates for 2027 have risen to $4.81 from $2.91. LQDA shares have surged 97.2% year to date.
Liquidia’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 54.40%.